XML 30 R19.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Equity Offerings | 3 Months Ended
--- | ---
Mar. 31, 2024
Equity Offerings |
Equity Offerings | Note 13. Equity Offerings Warrant Inducement Offer On January 9, 2023, the Company reduced the exercise price of certain existing warrants (the "Existing Warrants"), exercisable for 331,608 shares of the Company’s common stock held by a certain investor (the “Investor”), with exercise prices ranging from $14.00 to $526.50 per share to $4.00 per share (the "2023 Warrant Repricing"). In connection with the 2023 Warrant Repricing, the Company entered into a warrant inducement offer letter (the "2023 Inducement Letter"), with the Investor pursuant to which it would exercise up to all of the 331,608 Existing Warrants (the "Inducement Offer"). In consideration for exercising the Existing Warrants pursuant to the terms of the 2023 Inducement Letter, the Company received approximately $1.3 million in gross proceeds. The Company paid the placement agent aggregate cash fees of approximately $0.2 million related to the Inducement Offer which represented 8.0% of the gross proceeds received from the Inducement Offer plus other offering costs resulting in net proceeds to the Company of $1.1 million. In consideration for exercising the Existing Warrants pursuant to the terms of the 2023 Inducement Letter, the Company issued the Investor a new Series E common stock purchase warrant, or Series E Warrant (the "Series E Warrant"), to purchase 331,608 shares of common stock at an exercise price of $4.00 per share. The Series E Warrant is exercisable for five years from the date of stockholder approval. Exercise of the Series E Warrant in full was subject to approval of the Company's stockholders other than the Investor, which was obtained at a special meeting of the Company's stockholders held on March 21, 2023 (the "Stockholders' Meeting"). The incremental fair value of the repriced warrants amounted to $0.3 million and the fair value of Series E warrant totaled $1.9 million. The relative fair value of such amounts were recorded to additional paid-in capital concurrent with the exercise of the Existing Warrants. As a result of the 2023 Warrant Repricing and Inducement Offer, the Company presents a deemed dividend for the modification of Existing Warrants and issuance of the Series E Warrants of $0.8 million during the three months ended March 31, 2023. The deemed dividend was included in net loss attributable to common stockholders in the calculation of net loss per share in the unaudited consolidated condensed statements of operations. The warrants, other than the Series E Warrants which are presented in a separate table below, were valued on the date of the 2023 Warrant Repricing using the Black-Scholes model based on the following assumptions:
|  | 5/22/2020 Raise |  |  | 8/3/20 Raise |  |  | Series B |  |  | Series C |
Risk-free interest rate |  |  | 4.06 | % |  |  | 4.06 | % |  |  | 3.60 | % |  |  | 3.66 | %
Volatility |  |  | 135.35 | % |  |  | 132.55 | % |  |  | 115.42 | % |  |  | 127.65 | %
Expected dividend yield |  |  | 0.00 | % |  |  | 0.00 | % |  |  | 0.00 | % |  |  | 0.00 | %
Expected life (in years) |  |  | 2.4 |  |  |  | 2.6 |  |  |  | 6.5 |  |  |  | 4.5 |
The Series E warrants were also valued on the date of the 2023 Warrant Repricing at approximately $1.9 million using the Black-Scholes model based on the following assumptions:
Risk-free interest rate |  |  | 3.66 | %
Volatility |  |  | 124.07 | %
Expected dividend yield |  |  | 0.00 | %
Expected life (in years) |  |  | 5.0 |
Private Placement On January 9, 2023, the Company entered into a Securities Purchase Agreement (“Securities Purchase Agreement”) for a private placement (“Private Placement”), with the Investor. Pursuant to the Securities Purchase Agreement, the Investor agreed to purchase, for an aggregate purchase price of approximately $8.0 million, (a) Class A units at a price that was the lower of $3.00 per unit and 90% of the 5 day volume weighted average price of the Company’s common stock immediately prior to obtainment of the approval of the Company’s stockholders of conversion of the PIPE Preferred Stock and PIPE Warrants (as each are defined below), each consisting of one share of common stock, one Series F common stock purchase warrant, or Series F Warrant, and one Series G common stock purchase warrant, or Series G Warrant, and together with the Series F Warrants (the “PIPE Warrants”) and (b) Class B units at a price of $1,000 per unit, each consisting of one share of a new series of the Company’s preferred stock, designated as Series A Convertible Preferred Stock (the “PIPE Preferred Stock”), par value $0.0001, and one Series F Warrant and one Series G Warrant for each share of the Company’s common stock underlying the PIPE Preferred Stock (each share of which is convertible into a number of shares of the Company’s common stock equal to $1,000 divided by the lower of $3.00 and 90% of the 5 day volume weighted average closing price of the Company’s common stock immediately prior to the obtainment of the approval of the Company’s stockholders of conversion of the PIPE Preferred Stock and PIPE Warrants, or the Preferred Conversion Rate). The closing under the Securities Purchase Agreement and the sale and issuance of the Class A units and Class B units (and the issuance of any underlying common stock) were approved at the Stockholders’ Meeting. At the closing of the Private Placement, the Company issued 497,908 Class A units for proceeds of approximately $0.9 million and 7,203 Class B units for proceeds of approximately $7.1 million which were convertible into up to 4,501,060 shares of common stock, as well as the issuance of warrants described below. The PIPE Warrants, including Series F warrants and Series G warrants, are exercisable at an exercise price of $3.00 per share, subject to adjustments as provided under the terms of the PIPE Warrants. The PIPE Warrants are exercisable at any time on or after the closing date of the Private Placement until the expiration thereof, except that the PIPE Warrants cannot be exercised if, after giving effect thereto, the purchaser would beneficially own more than 4.99%, or the Maximum Percentage, of the outstanding shares of common stock of the Company, which Maximum Percentage may be increased or decreased by the purchaser with written notice to the Company to any other percentage specified not in excess of 9.99%. The Series F Warrants have a term of two years from the date of stockholder approval, and the Series G Warrants have a term of six years from the date of stockholder approval. The Series F Warrants and Series G Warrants were approved at the Stockholders’ Meeting. The Series F warrants and Series G warrants were valued, in aggregate, at approximately $5.5 million using the Black-Scholes model based on the following assumptions:
|  | Series F |  |  | Series G |
Risk-free interest rate |  |  | 3.8 | % |  |  | 3.4 | %
Volatility |  |  | 80.0 | % |  |  | 74.0 | %
Expected dividend yield |  |  | 0.0 | % |  |  | 0.0 | %
Expected life (in years) |  |  | 2.0 |  |  |  | 6.0 |
The proceeds from the Securities Purchase Agreement were allocated to the equity instruments issued based on their relative fair values and recorded in additional paid-in capital. Shares of PIPE Preferred Stock, the conversion of which was approved at the Stockholders’ Meeting, convert into common stock at the option of the holder at the Preferred Conversion Rate, subject to certain ownership limitations as described below. The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. Subject to limited exceptions, holders of shares of PIPE Preferred Stock will not have the right to convert any portion of their Preferred Stock if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or up to 9.99% at the election of the holder) of the number of shares of the Company’s common stock outstanding immediately after giving effect to its conversion. Holders of PIPE Preferred Stock will be entitled to receive dividends on shares of PIPE Preferred Stock equal, on an as-if-converted-to-common stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the PIPE Preferred Stock does not have voting rights. The Company also entered into a registration rights agreement with the purchasers requiring the Company to register the resale of the shares of common stock, the shares issuable upon exercise of the Warrants and the shares issuable upon the conversion of the PIPE Preferred Stock. Placement Fees In connection with offerings completed by the Company in 2022, (the "2022 Offerings"), the Company entered into an agreement with a placement agent that, subject to satisfaction of the requirements contained therein, called for a placement fee payable based on capital raised from certain investors for a definitive time following the expiration of the agreement. The accrued placement fee of approximately $1.4 million related to the 2022 Offerings is included in accrued expenses in the consolidated balance sheet as of March 31, 2024. Additionally, the agreement called for the issuance of warrants with the following terms:
Number of shares |  | Exercise Price |  | Expiration
33,000 |  | $31.25 |  | 5 years
31,000 |  | $17.50 |  | 5 years
The warrants were valued on the date of the 2022 Offerings using the Black-Scholes model based on the following assumptions:
Value ( $ in millions) |  | Expected Volatility |  | Risk-Free Interest Rate |  | Expected Dividend Yield |  | Expected Term (years)
$0.4 |  | 93.25% |  | 1.81% |  | 0% |  | 5.0
$0.2 |  | 96.70% |  | 2.87% |  | 0% |  | 5.0
The warrants have not been issued by the Company as of March 31, 2024. Warrants The following table presents the number of common stock warrants outstanding:
Warrants outstanding, December 31, 2022 |  |  | 1,150,658 |
Issued |  |  | 10,329,794 |
Exercised |  |  | (331,608 | )
Expired |  |  | (106,707 | )
Warrants outstanding, December 31, 2023 |  |  | 11,042,137 |
Issued |  |  | — |
Exercised |  |  | — |
Expired |  |  | — |
Warrants outstanding, March 31, 2024 |  |  | 11,042,137 |
The following table presents the number and type of common stock warrants outstanding, their exercise price, and expiration dates as of March 31, 2024:
Warrant Type |  | Warrants Outstanding |  |  | Exercise Price |  |  | Expiration Date |
May 2020 Warrants |  |  | 12,743 |  |  | $ | 562.50 |  |  | 5/20/2025 |
May 2020 Placement Agent Warrants |  |  | 1,244 |  |  | $ | 703.13 |  |  | 5/20/2025 |
August 2020 Warrants |  |  | 19,407 |  |  | $ | 437.50 |  |  | 8/3/2025 |
August 2020 Placement Agent Warrants |  |  | 1,918 |  |  | $ | 546.88 |  |  | 7/30/2025 |
August 2021 Pharos Banker Warrants |  |  | 1,484 |  |  | $ | 149.50 |  |  | 8/16/2026 |
February 2022 Series B Warrants |  |  | 391,527 |  |  | $ | 14.00 |  |  | 2/4/2029 |
July 2022 Series C Warrants |  |  | 284,020 |  |  | $ | 14.00 |  |  | 7/22/2027 |
January 2023 Series E Warrants |  |  | 331,608 |  |  | $ | 4.00 |  |  | 3/21/2028 |
March 2023 Series F Warrants |  |  | 4,999,093 |  |  | $ | 3.00 |  |  | 3/21/2025 |
March 2023 Series G Warrants |  |  | 4,999,093 |  |  | $ | 3.00 |  |  | 3/21/2029 |
|  |  | 11,042,137 |  |  |  |  |  |  |  |
As of March 31, 2024, the warrants issued by the Company had a weighted average exercise price of $5.31.

X
- References No definition available. + Details
Name: | rmed_EquityOfferingsAbstract
Namespace Prefix: | rmed_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent + Details
Name: | us-gaap_PreferredStockTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration